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Acute superior mesenteric venous thrombosis (ASMVT) is a rare but potentially lethal abdominal ca-
lamity. Outcome depends on prompt recognition and revascularization before progresses to bowel
gangrene. Despite better understanding of pathogenesis and development of modern treatment tech-
nique, management of ASMVT remains a great clinical challenge. Transcatheter thrombolysis as the main
revascularization method, combined with mechanical thrombectomy and other endovascular manipu-
lations, alone or as a hybrid procedure, has got favorable outcomes. Thus on the basis of early diagnosis
and close evaluation of intestinal ischemia and thrombus evolution, a coordinated stepwise management
strategy involving a specialized approach of initial anticoagulation, preferred endovascular therapy, and
damage-control surgery modality with surgical thrombectomy, may show beneﬁts in rapid revascular-
ization, prompt symptom improvement, and short bowel syndrome avoidance, with shortened hospi-
talization and less cost. This article presents an evidence-based review of the state-of-the-art
advancements of this transcatheter thrombolysis centered stepwise management strategy for ASMVT.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Acute mesenteric ischemia (AMI) is an abdominal vascular
emergency comparable to myocardial infarction or apoplexy.
Mesenteric venous thrombosis (MVT) is the least common, about
9e16%, among four types of AMI, typically affecting the superior
mesenteric vein and rarely the inferior mesenteric vein [1]. It
approximately accounts for 1 in 5000 to 15,000 inpatient admis-
sions, 1 in 1000 emergency department admissions [2]. Intestinal
gangrene caused by mesenteric venous occlusion and treated by
bowel resection was ﬁrst reported by Elliot in 1895 [3]. But it was
after the detailed description byWarren and Eberhardt in 1935 that
MVT became a distinct clinical entity [4]. In 1960, it was demon-
strated by Barritt and Jordan that manifest venous thromboembo-
lism must be treated [5]. In Sweden, incidence of MVT has
increased from 2.0 per 100,000 patient-years between 1970 and
1982 to 2.7 per 100,000 patient-years between 2000 and 2006,
with equal incidence in both genders and highest incidence in the
age category 70e79 years [6]. Poor understanding of its naturalng), xingjiangwu@gmail.com
by Elsevier Ltd. All rights reservedhistory and clinical trait and unacceptable delay before treatment
are main reasons for its high mortality.
Acute superior mesenteric venous thrombosis (ASMVT) is usu-
ally segmental with hyperemia and hemorrhage of the bowel wall
[7]. It leads to increased anaerobic metabolism, regional acidosis,
focal sloughing of mucosa and initial hyperperistalsis with
cramping pain and gut emptying, followed by intense ischemic
pain from the secondary arteriospasm and transmural hypo-
perfusion [8]. Symptoms may vary from insidious onset of vague
generalized to sudden onset of localized, severe and constant
abdominal pain with vomiting and diarrhea. Bowel wall edema
increased outﬂow resistance and blood viscosity, impeding arterial
ﬂow and resulting in bowel infarction [9]. Massive ﬂuid inﬂux into
the bowel wall and lumen leads to systemic hypovolemia and
hemoconcentration. During initial phase, peritoneal signs are not
found on physical examination, with the classic “pain out of pro-
portion to physical ﬁndings”. In the later stages with peritonitis and
localized abdominal pain, presence of associated physical ﬁndings
occur [10].
The etiology of ASMVT can be categorized based on Virchow’s
triad of venous stasis, hypercoagulable state and endothelial injury,
which may often coexist, as any venous thrombotic condition
(Table 1) [11,12]. Local inﬂammatory factors are often associated
with initial thrombus formation in the trunk of superior mesenteric.
Table 1
Etiology and predisposing factors of acute superior mesenteric venous thrombosis.
Mesenteric venous stasis Hypercoagulable states Endothelial injury
Inherited Acquired
➢ BuddeChiari syndrome
➢ Cirrhosis-associated
portal hypertension
➢ Splenectomy
➢ Congenital stenosis
 Factor V Leiden gene mutation
 Hyperhomocysteinemia
 Hyperﬁbrinogenemia
 Paroxysmal
 Nocturnal hemoglobinuria
 Antithrombin III deﬁciency
 Protein C/S deﬁciency
 Antiphospholipid or anticardiolipin
antibody syndromes
 Factor II mutation (G20210A)
 Methylenetetrahydrofolate reductase
(MTHR) gene mutation
 Collagen vascular disease
 Dysﬁbrinogenemia
 Malignancy
 Myeloproliferative disorders
 Oral contraceptive medications
 Pregnancy
A Intra-abdominal inﬂammatory disease
A Pancreatitis
A Cholecystitis
A Diverticulitis
A Colitis
A Direct injury by manipulation of
mesenteric/portal vein
A Splenectomy
A Surgical shunts
A Liver transplantation
A Other abdominal operations
A Abdominal trauma
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REVIEWvein (SMV) and portal vein. Whereas hypercoagulability leads to
thrombosis beginning from the intramural venules, vasa recta and
venous arcades [2]. Older age, acidosis, renal failure, diabetes
mellitus, use of digoxine or antiplatelet drugs, duration of the
symptoms before surgery, shock, low pH value, and re-laparotomy
were found to be negative predictors of perioperative mortality of
AMI [13,14]. In a statistical mortality analysis of MVT, the predictor
of early and late mortality is colonic involvement with anti-
coagulation failure and short-bowel syndrome (SBS) [15]. The
overall mortality has ranged from 29% to 38% for surgical treatment
and 13%e19% for nonoperative management [16].
Once intestinal infarction occurs from venous engorgement and
impeded arterial ﬂow, there are few options to relieve venous
congestion. Therefore, it may bemore difﬁcult to manageMVT than
mesenteric ischemia of arterial source. In ACC/AHA 2005 practice
guidelines for management of peripheral vascular disease, recom-
mendations about treatment of AMI are offered, but without a
formal discussion on ASMVT as there are few level I or II data [17].
At present, there is no optimal treatment algorithm or guideline of
MVT. Endovascular therapy, alone or as a hybrid procedure, has got
favorable outcome in recent two decades [18]. Recent improvement
in imaging techniques and better understanding of etiology have
led to a dramatic policy tendency to non-operative management
[19]. The stepwise treatment strategy evolving from two most
advanced surgical notions, the minimally invasive surgery and
damage control surgery, has shown great advance in surgical
therapy of inﬂammatory bowel disease and acute pancreatitis
[20,21]. This review collects the up-to-date evidences to outline the
endovascular therapy centered stepwise management strategy of
ASMVT.
2. Assessment of thrombus evolution and intestinal viability
The throughout surveillance of intestinal reperfusion and
thrombus evolution guides the step-up of treatment. The evalua-
tion method itself develops from noninvasive portography to sur-
gical exploration as well. Recent widespread use of contrast-
enhanced computed tomography (CT) portography has facilitated
early detection of ASMVT before laparotomy from 1 week in 1978e
1995 to 1 day in 1995e2003, with a sensitivity over 90% [22]. It has
become an effective assessment tool of both intestinal viability and
thrombolysis response (Fig. 1A, B, E, F). The bowel segment with a
homogenous, non-enhancing appearance represents necrotic
bowel, whereas ischemic bowel is identiﬁed by layered enhance-
ment pattern [23]. Digital subtraction angiography (DSA) portog-
raphy, the gold-standard of MVT diagnosis, is reserved for equivocalcases on non-invasive imaging and also used in conjunction with
catheter-directed thrombolysis (Fig. 1C, D, G, H). The “thumprinting
sign” on plain ﬁlm and elevated serum lactate level are nonspeciﬁc
and of limited value. During thrombolysis, coagulation should be
closely monitored.
Since the need to preserve as much bowel as possible against
being overly aggressive in resecting any questionably viable bowel,
intraoperative assessment of bowel viability is of great signiﬁcance.
It consists of initial clinical evaluation then assessment for visible
and palpable pulsations in the mesenteric arcade, normal color and
appearance of the bowel serosa, peristalsis, and bleeding from cut
surfaces. Nevertheless, each of these clinical judgments is subjec-
tive and inaccurate, with a sensitivity of only 82% and a speciﬁcity
of 91% [24]. A nonviable segment could be implied with absence of
pulsatile signals on the antimesenteric border detected by a
continuous-wave 9e10 MHz Doppler ultrasound probe [25]. Highly
accurate intraoperative quantiﬁcation of intestinal perfusion using
ﬂuorescein and a perfusion ﬂuorometer or laser Doppler ﬂowmeter
has been proposed, but less practical for routine use as special
equipment requirements and technical difﬁculties [26,27]. The
most recently developed intra-operative indocyanine green angi-
ography, HyperEye Medical System (HEMS), has a unique and
practical advantage in assessment of intestinal wall perfusion with
a longer duration for imaging [28]. Upon completion of surgical
revascularization, 20 min of reperfusion time should be permitted
and then bowel viability must be reassessed [29].
Even after reperfusion and careful assessment, bowel viability it
be determined with certainty at initial exploration. The second-
look laparotomy in 24e48 h postoperatively was advocated to
assess questionable viability and rethrombosis in 1971 [30]. The
modern option of deferring bowel resection and reanastamosis and
high rate of postoperative rethrombosis underscores the funda-
mental essentiality of a mandatory second-look procedure. The
frequency of bowel resection is higher during second-look surgery
than initial exploration and surgical revascularization (53% vs 31%)
[13]. In another study of 31 cases of ASMVT, thrombosis recurred in
36% patients during the second-look exploration [31]. Once
deciding to perform a second-look laparotomy, it should be ﬁrmly
carried out because a signiﬁcant proportion of patients without
signs of clinical deterioration at this time do require further bowel
resection. However, such a second-look operation is not always
favorable and safe due to extra strikes of reoperation. Laparotomy
itself is also a predisposing factor for MVT and only 23.5%
rethrombosis rate of second-look surgery was reported in another
study [32]. It is controversial about the routine use of second-look
laparotomy.
Fig. 1. Portography at admission and after transcatheter thrombolysis A, B: thrombus (white arrow) within the superior mesenteric vein (SMV) trunk and branches on coronal and
axial contrast-enhanced CT images at admission, bowel edema identiﬁed by layered enhancement pattern. C: pre-thrombolysis direct portal venography via percutaneous
transhepatic approach shows extensive thrombosis within SMV, portal vein and splenic vein with slight collateral drainage (black arrow). D: pretreatment digital subtraction
superior mesenteric artery (SMA) angiogram shows patent SMA and the portal vein faintly opaciﬁed with ﬁlling defect in the delayed venous phase without visualization of the
SMV, and remarkable pooling of contrast medium at the small intestine. E, F: CT image at the same level as A, B after thrombolytic therapy shows the wide patent SMV and portal
vein (white arrow) with no obvious residual thrombus. G: direct portal venography via the infusion catheter (white arrow) after thrombolysis shows patent PV and SMV with no
thrombus (white arrow). H: improved visualization of the portal vein as well as the primary, secondary, and tertiary branches of the SMV.
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REVIEWIn recent years, laparoscopy is used as a safe, expedient, mini-
mally invasive, and direct-viewed method for initial and second-
look exploration, even at bedside of intensive care unit (ICU) un-
der local anesthesia [33,34]. Combined urokinase and laparoscopic
therapy has been an effect treatment of acute superior mesenteric
artery occlusion since 1996 [35]. CT-angiography combined with
early laparoscopic exploration and thrombolytic treatment have
beneﬁcial effects regarding mortality compared to early bowel
resection with thrombectomy [36]. It is more widely applied for
second-look exploration with shortened operating time, and min-
imal physiological disturbance [37,38]. Leaving the laparoscopic
port in place after initial evaluation may enable a quick and easy
second-look after local thrombolytic therapy [36]. Some authors
considered that laparoscopic second-look intervention could
totally replaced second-look laparotomy as the routine procedure
[39]. However, evidence-based guidelines of the european associ-
ation for endoscopic surgery in 2006 pointed out that since
radiographic imaging accurately identiﬁed most cases of mesen-
teric ischemia, it is unlikely that diagnostic laparoscopy will pre-
vent a negative laparotomy [40]. Extensive intestinal paralysis with
dilated bowel loops may be impossible to evaluate at laparoscopy.
Actually, laparoscopy manipulation itself is a remarkable cause of
ASMVT [41,42]. It is imprudent to draw the conclusion at present as
there is no control study of laparoscopy versus open surgery for
initial or second-look exploration in ASMVT patients. Moreover,
intra-abdominal pressure during laparoscopy cannot exceed
20 mmHg to avoid exacerbation of intestinal hypoperfusion.
Enteroscopy is recommended as adjuvant tool to detect the early
mucosal ischemia.3. Stepwise treatment algorithm
3.1. Step 1: systemic anticoagulation and intensive care
3.1.1. Anticoagulation
Immediate anticoagulation, initiation of an unfractionated
heparin bolus followed by continuous infusion, is the ﬁrst step and
cornerstone of the stepwise management strategy. It has been
recognized as the mainstay therapy of MVT since postoperativeanticoagulation was demonstrated to reduce the mortality and
reverse the bowel without transmural necrosis in 1986 [43]. Similar
to treating venous thrombosis in other locations, anticoagulation
for ASMVT is to stop extension of the thrombotic process and give
room for normal ﬁbrinolytic activity, which means rapid heparin-
ization as soon as diagnosis. Early animal experiments of SMV oc-
clusion has indicated that heparin limited clot propagation and
enhanced collateral venous drainage [44]. Recent clinical studies
found early anticoagulation could assist recanalization and lower
recurrence rate of portomesenteric venous thrombosis [45,46]. In a
retrospective study, 80% of anticoagulated patients of MVT showed
recanalization over a mean follow-up time of 5 months compared
with <10% of non-anticoagulated patients [47]. Initial anti-
coagulation has shown superiority of early recanalization, low risk
of SBS, and shortened hospitalization over prompt surgery in a
series of clinical control studies [48e51]. For patients with sus-
pected bowel infarction, initial anticoagulation and delayed short-
segment bowel resection for stricture could also be an appropriate
procedure to limit excessive resection [52]. Patients with MTV have
a low mortality and recurrence receiving oral anticoagulation with
vitamin K antagonist [53]. It should be started immediately at
heparinization when surgery becomes unnecessary. Currently,
controversy remains regarding early and long-term anticoagulation
in MVT patients of hepatic cirrhosis because of high risk of hem-
orrhea [54].3.1.2. Intensive care management
Every patient with ASMVT should receive emergent treatment
in a surgical ICU. Fluid resuscitation should be commenced
immediately with intravenous crystalloids and blood products
under proper monitoring to stabilize hemodynamics as general
endothelial disintegration within a few hours leading to volume
displacement. Damage control resuscitation characterized by
permissive hypotension, limiting crystalloid intravenous ﬂuids, and
delivering higher ratios of plasma and platelets to red blood cells is
recommended for critically ill patients [55]. Painmust be dealt with
adequately. Nasogastric suction is applied to diminish the bowel
movements as well as intraluminal pressure. Broad-spectrum
prophylactic antibiotics (e.g. second-generation cephalosporin
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REVIEWplus metronidazole) are administered. Fluid, electrolyte, and acid-
base balance are adequately corrected. Prostaglandin E1 and
dextran are used to improve microcirculation in addition to volume
expansion. It has been shown in animal experiments, but no
extensive test in humans, that intravenous glucagon administration
could increase cardiac output and ﬂow to all layers of intestine
thereby improving survival of AMI [56]. Vasopressors and so-
matostatin are contraindicant to avoid exacerbating intestinal cir-
culatory compromise [57].3.2. Step 2: endovascular therapy
Persistent worsening of abdominal pain despite 48e72 h of
systemic anticoagulation or high risk of bowel infarction at
admission are indications to step up to endovascular therapies.
With rapid development of endovascular treatment technique and
device, patients with high suspicion of bowel necrosis could receive
endovascular therapy to achieve prompt recanalization under
appropriate general conditions. This strategy aims to salvage more
potentially reversible segments and avoid the dramatic attack of
early operation. New criteria for prompt surgery has been sug-
gested as bowel-wall thickness and bowel-wall enhancement on
the arterial phase of CT because peritonitis may not strictly corre-
late with bowel infarction. In 2005, Hollingshead et al. retrospec-
tively studied 20 patients with transcatheter thrombolysis [58].
Three patients had complete resolution, 12 had partial resolution,
and 5 had no resolution. 85% had resolution of symptoms. No pa-
tients required bowel resection after thrombolytic therapy.
Currently, endovascular thrombolysis has been the core method of
recanalization of this stepwise management strategy. Literature
reports on endovascular therapy of MVT has continued to increase
(Table 2).
There 4 routes of endovascular therapy for ASMVT: percuta-
neous transhepatic (PT), transjugular intrahepatic portosystemic
shunt (TIPS), SMA, intraoperative catheterization. Under ultra-
sound or X-ray guidance, PTaccess is technically easier and prone to
remove larger thrombus within the trunk of SMV [59e61]. But coil
embolization of the tract is required to prevent intraperitoneal or
subcapsular hemorrhage as this approach traverses hepatic capsule
and followed by thrombolysis [62,63]. For patients with ascites or
coagulation disorder, TIPS approach is safer and allows additional
manipulations such as venoplasty and stent placement for elastic
recoil or stenosis [64]. Despite the technical difﬁculty and potential
risk of hepatic function injury and intra-abdominal bleeding, it is
the most widely used manner [65]. Indirect thrombolytic therapy
via SMA is technically simpler and more efﬁcient in resolving
thrombi within capillaries and venules [66]. Moreover, papaverine
can be selectively administered into SMA to relieve the secondary
mesenteric arteriospasm. However, this approach may result in
lytic agents diverting through patent branches or collaterals and
prolongation of thrombolysis [67]. Endovascular mechanical ma-
nipulations (e.g. mechanical thrombectomy, stent implantation,
angioplasty, TIPS creation and aspiration thrombectomy) have
evolved as a signiﬁcant part of thrombolysis to augment the ability
of rapid thrombus removal, particularly when there is a structural
reason. Rapid thrombus dissolution can be achieved by TIPS and
stent placement to create a low-pressure run-off [68]. However,
complicated endovascular manipulations may cause acute injury to
vessel wall thereby promoting thrombus reformation and bleeding.
Aspiration thrombectomy is recommended due to its minor injury
and high efﬁciency. Newer mechanical thrombectomy devices such
as the AngioJet reholytic mechanical thrombectomy system
(Possis Medical) has demonstrated promising results with a com-
plete resolution of a MVT [69].Endovascular therapy has increased signiﬁcantly in the modern
era and altered the management of AMI [70]. Compared to open
surgery, endovascular treatment is associated with decreased
mortality, lower rates of bowel resection and total parenteral
nutrition, and shorter length of stay [71]. Early revascularization by
endovascular technique is still utilized in severe AMI patients [72].
However, successful use of endovascular treatments needs
a preexisting standard algorithm with adequate equipment and
timely stafﬁng at the emergency center.
3.3. Step 3: damage control surgery
Emergency operation is imperative for patients with diffuse,
severe peritonitis and bloody vomit, stool and ascites, which are
signs of transmural infraction or perforation [73]. During endo-
vascular procedure, prompt laparotomy is indicated in patients
who develop new or worsening signs of peritonitis, particularly in
those who have complete occlusion of the main trunk of the SMV.
Delayed bowel resection may be needed after mesenteric recana-
lization due to the secondary stricture [58]. Multiple bowel seg-
ments are commonly affected and bowel viability in the transient
zone is hard to determine. Before 1990s, resection and primary
anastomosis was the standard procedure, with high thrombus
recurrence rate at the anastomotic site. Extensive resection is often
forced to operate with poor prognosis and high risk of SBS. A
mandatory second-look procedure is still debatable.
Damage control surgery is well established in the trauma setting
and extends to many nontraumatic areas [74,75]. It has been
advocated as an option to improve the survival of AMI patients
requiring laparotomy since 2005 [76]. A damage-control approach
for ASMVT involves 3 consecutive phases (Fig. 2). Phase 1: emer-
gency resection of bowel and other organs with clear transmural
necrosis and intraoperative thrombectomy with no attempt to
restore gastrointestinal continuity. Some authors recommend
resection by stapling and dividing at healthy margins. The stapled
bowel ends are simply returned to abdomenwith peritoneal lavage
performed. Anastamosis are deferred until second or third-look
laparotomy at 24e48 h to make certain further necrosis and fail-
ure of anastomosis do not occur [8,76e78]. Expeditious temporary,
skin-only, abdominal wall closure with an V.A.C. dressing system
or “Bogota bag” sandwich technique can be applied [76,77]. Due to
the constant bacterial translocation caused by growing intra-
luminal pressure of stapled bowel ends and need of reoperation to
assess the bowel viability, resection and double ileostomy is
preferred as an alternative approach for poor risk patients [79,80].
For patients with high of risk of abdominal compartment syn-
drome, open abdomen technique is recommended [81]. This mo-
dality enables the patient to avoid the risk of anastomotic
insufﬁciency following primary anastomosis as well as the hazards
related to a second-look operation owing to the direct observations
of the color tone of the double ileostomy or from the open
abdomen. Intravenous administration of heparin for anti-
coagulation to prevent rethrombosis of mesenteric vessels should
initiate early with damage control closures despite the risk of
hemorrhage. Phase 2: prompt transfer to a surgical ICU for venti-
lation, rewarming, inotropic support, correction of coagulopathy
and dialysis as indicated. Further postoperative critical care man-
agement to maintain hemodynamical stability with organ function
and nutrition support are performed. Angiography is arranged to
plan transcatheter thrombolysis in an attempt to salvage more
ischemic bowel [76]. Thrombus evolution must be continuously
assessed by contrast-enhanced CT portography throughout the
thrombolysis. Phase 3: If the bowel perfusion is well restored in a
short time, deﬁnite anastomosis can be completed in 72 h to 1
week. For patients with major ischemia-reperfusion injury, deﬁnite
Table 2
Author, Year N Intervention Agent Route Duration Total dose Lysis outcome Surgery Complication
Yankes JR, 1988 1 Thrombolysis þ
angioplastic
dilatation
UK PT 4 h 9.6 million Complete Laparotomy þ ileal resection None
Bilbao, 1989 1 Thrombolysis UK PT 12 h 2.2 million U Complete None None
Bizollon, 1991 1 Thrombolysis rt-PA PT Bolus once 20 mg Complete None None
Mies, 1991 1 Thrombolysis rt-PA SIV þ SMA Bolus once 100 mg þ 50 mg Complete None None
Suzuki, 1992 2 Thrombolysis UK SIV 3 d 2.2 million U Complete None None
Demertzis, 1994 1 Thrombectomy þ
thrombolysis
rt-PA Intraoperative
SMV catheter
2 d postoperatively 50 mg bolus þ
200 mg
Complete Exploratory laparotomy þ
bowel resection
None
Rivitz, 1995 1 Thrombolysis UK TI 2 d 5.75 million U Complete Exploratory laparotomy None
Miyazaki Y, 1995 1 Thrombolysis rt-PA, UK SIV 0.5 d þ 6 d 3000 million U þ
25.2 million U
Complete None None
Al Haq, 1996 1 Thrombolysis SK SIV 3 d 7.5 million U Complete None None
Poplausky, 1996 1 Thrombolysis UK SMA 2 d 4.8 million U Complete None None
Klempnauer J, 1997 5 Thrombectomy þ
thrombolysis
rt-PA Intraoperative
SMV catheter
2-3 d 70e100 mg Complete Exploratory laparotomy None
Train, 1998 1 Thrombolysis UK SMA 5 d 14.7 million U Complete None None
Guckelberger, 1999 1 Thrombolysis rt-PA SIV 10 d 200 mg Complete None None
Ludwig, 1999 1 Thrombolysis UK SMA 4 d 9.8 million U Complete None None
Rosen, 2000 1 Thrombolysis þ
thrombectomy
rt-PA SMA þ PT 16 h 18 mg Partial None None
Schafer, 2000 1 Thrombolysis UK SIV 7 d 3 million U Complete None None
Sze, 2000 1 Thrombolysis þ TIPS UK SMA 16 h 1.6 million U Partial Laparotomy þ jejunum
resection
GI bleeding
Sehga, 2000 1 Thrombolysis UK TI 1 d 4.3 million U Partial None None
Antoch, 2001 3 Thrombolysis UK SMA 5-8 d 16.8 million U 2 Complete þ
1 partial
None Bleeding at the catheter
site in 1 case
Tateishi, 2001 1 Thrombolysis UK SIV þ SMA 3 d þ 11 d 2.8 million U Partial Exploratory laparotomy None
Ayetkin, 2001 1 Thrombolysis UK TI 4 h 1.7 million U Complete None Portal cavernoma
Kercher, 2002 1 Thrombolysis UK PT 45 h 56.5 million U Complete None None
Lopera, 2002 3 Thrombolysis þ
thrombectomy
UK PT 36 36 million U Complete None None
Liu B, 2003 2 Thrombolysis UK SMA 7 d 60-70 million U Complete None None
Henao, 2003 1 Thrombolysis rt-PA SMA 2 d 96 mg Complete None None
Atsuko, 2003 1 Thrombolysis UK TI 40 d 8.4 million U Complete Stenotic bowel resection None
Espeel B, 2004 2 Thrombolysis rt-PA SMA 17e24 h 34-51 mg Complete Bowel resection None
Kaplan, 2004 1 Thrombolysis rt-PA Intraoperative
SMV catheter
44 h 40 mg Complete Exploratory laparotomy None
Hyun, 2005 11 7 Thrombectomy,
10 thrombolysis
UK, t-PA, rt-PA PT UK 0.33e45 h,
t-PA 0.33e45 h,
rt-PA 29e45 h
0.41e34 million U,
3.3e2250 mg,
420.5e1350 U
10 complete þ
1 none
None 1 Hemothorax
Naoto, 2005 1 Thrombectomy þ
thrombolysis
UK PT 3 d 7.2 million U Complete Bowel resection None
Alfredo, 2005 1 Thrombolysis rt-PA PT 3 h 90 mg Complete None Suspected cerebral hemorrhage
Michael, 2005 20 Thrombolysis UK, t-PA PT, SMA UK 23e72 h,
t-PA 2.3e48 h
18.4e135 million U,
4e41 mg
3 Complete þ
12 partial þ
5 none
None 9 transfusion requirement,
2 bleeding, 2 dislodged catheters,
1 death due to septic shock and
GI hemorrhage
Ozdogan, 2006 1 Thrombolysis SK Intraoperative
SMV catheter
2 bolus 30 million U Complete Exploratory and
second-look
laparotomy
None
Wei Zhou, 2007 2 Thrombectomy þ
angioplasty þ
thrombolysis
t-PA PT Bolus in 1 caseþ
2 d in 1 case
2 mg bolus þ36 mg Complete None None
Ferro C, 2007 1 Thrombectomy þ
thrombolysis
UK TI 7 d 2 million U bolus þ
4.9 million U
Complete None None
Nakayama, 2008 1 e TI e e Complete None None
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REVIEWoperation is accomplished after 2e4 months of enteral nutrition
therapy because these patients are at high risk of chronic mesen-
teric rethrombosis [80]. Side-to-side stapled anastomosis is pref-
erable because it strongly reduces anastomotic leak rates [82].
Operative thrombectomy, which was ﬁrst reported by Mer-
genthaler and Harris in 1968, is an important part of damage
control surgery for ASMVT [83]. It is carried out in order to
immediately reduce thrombus burden, especially in the case
involving portal venous reconstructions, such as liver trans-
plantation. In one case series, surgical thrombectomy was carried
out in six patients with acute porto-mesenteric thrombosis after
liver transplantation, with a success rate of 83%, demonstrating its
high efﬁcacy [84]. In addition, operative thrombectomy affords the
surgeon an opportunity to inspect the vascular anastomosis site.
[85] Thrombectomy can help decrease a large clot burden limited to
the larger vessels, but otherwise nontherapeutic for the venous
arcades and vasa recta [85]. As small adherent thrombi attached to
the vessel wall are extremely difﬁcult to completely remove and
serve as a nidus for thrombus propagation, the trend is thus to
infuse thrombolytics to treat these undetected foci of thrombus
[86].
This damage control surgery approach has a number of advan-
tages in surgical treatment of ASMVT. Patients spend a relatively
short period of time in the operating theater undergoing the insult
of major surgery. There is opportunity to correct multi-organ fail-
ure, acidosis, coagulopathy and hypothermia in ICU prior to
deﬁnitive operation. Moreover, the omentum can be retracted su-
periorly and bowel is observed directly through the dressing.
Wound closure is tension free so problems related to abdominal
compartment syndrome are avoided. Finally, infusion catheter can
be placed into the superior mesenteric vein intraoperatively to
facilitate postoperative portography and multiple endovascular
therapy. Endovascular thrombolysis are implemented as hybrid
procedures to reserve more questionable bowel thereby to avoid
SBS, and prevent progression or further development of the
thrombosis postoperatively [80].
3.4. Step 4: postreperfusion care
In the initial postoperative phase it is particularly important to
be vigilant of ischemia-reperfusion injury on abdominal, cardiac,
pulmonary and renal function, which may extend to a potentially
lethal multiple organ dysfunction syndrome [18]. Patients should
be managed in SICU with close monitoring and support to prevent
andmanagemultiple organ dysfunction. Some authors recommend
use of oxygen free-radical scavengers (e.g. allopurinol, angiotensin-
converting enzyme inhibitors) [7]. Local infection and bacterial
translocation may lead to a septic clinical episode requiring artiﬁ-
cial ventilation and dialysis in the longer term. Intravenous heparin
and broad spectrum antibiotics commenced preoperatively should
be continued until culture results are available and adjusted
accordingly [87]. Infusion of vasodilators such as intravenous
glucagon or intra-arterial papaverine is continued under hemody-
namically stable conditions [88]. Fluid balance and serum electro-
lytes are supposed to be monitored closely and corrected. Wound
care must be taken carefully, particularly in patients with enter-
ostomy and open abdomen. Total parental nutrition needs to be
managed by specialist teams. Early enteral nutrition should be
introduced as soon as possible to protect intestinal mucosal func-
tion [89]. The intestinal juice from proximal stoma is collected and
transfused back to the distal stoma. Anticoagulation should be
continued in the postoperative period to prevent rethrombosis of
mesenteric vessels in all patients unless there are contraindica-
tions. Oral anticoagulation therapy of warfarin is maintained for 6
months after discharge for patients with known reversible factors
Fig. 2. Damage control surgery modality for acute superior mesenteric venous thrombosis A. bowel resection of clearly transmural necrotic segments. B. intraoperative throm-
bectomy to remove as much as possible thrombus. C. bowel resection and double ileostomy instead of primary anastomosis. The intestinal juice from proximal stoma is collected
and transfused back to the distal stoma.
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REVIEWbut permanently for patients who is idiopathetic or with throm-
bophilia, with the international normalized ratio (INR) 2e3 times
the control value to conﬁrm satisfactory anticoagulation level
[90,91].4. Complications
Hemorrhage, wound infection, sepsis, re-thrombosis, SBS are
most common complications. In patients with peritoneal signs, the
morbidity is as high as 32e71% [92]. ASMVT patients who undergo
extensive bowel resection are often left with SBS, despite less
common thanmesenteric arterial ischemia [93]. In mayo clinic case
series of MVT, the incidence of SBS is 26%, in signiﬁcant correlation
with 30-day and 5-year mortality [15,31]. Bleeding during anti-
coagulation alone is less than 10% and related to the underlying
high risks of hemorrhage [22,94]. Gastrointestinal bleeding, espe-
cially in the mucosa necrosis site, is the most common type, but
hardly associated with death except the intracanial hemorrhage.
Undoubtedly, local anticoagulation together with thrombolysis
increases the possibility of massive hemorrhage. However, there
are no comparative data on different thrombolytics, dosage orFig. 3. Schema of endovascular therapy centered stepwise managemintervention routes and the risk of hemorrhage among ASMVT
patients at present. The available data from current reports are
conﬂicting. In one report on use of urokinase or recombinant tissue
plasminogen activator for catheter-directed peripheral arterial and
venous thrombolysis, the rate of intracanial hemorrhage reached
1.2% [95]. Hollingshead et al. reported a high bleeding rate of 60%,
with 1 death from gastrointestinal bleeding, in 20 cases of trans-
catheter thrombolysis for ASMVT [58]. But there are only 2 and 4
bleeding episodes during thrombolysis in other two reports of 32
and 11 porto-mesenteric thrombosis patients [96,97]. Re-
thrombosis rate is 0e25% in ASMVT but decreases to 0e3% with
continuous anticoagulation [46]. Approximately 14% of patients
who undergo resection have repeated MVT within 6 weeks [98].
Innate thrombophilia and oral contraceptive are known factors of
thrombosis recurrence [94].5. Summary and prospect
As a regular process from technical innovation to strategy
optimization during the treatment evolution, management strategy
update is inevitable for ASMVT with rapid development of high-ent strategy for acute superior mesenteric venous thrombosis.
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REVIEWresolution CT scan, laparoscope, endovascular techniques and bet-
ter understanding of pathophysiological processes. This life-saving
and gut-conserving strategy meets the principle of early MVT
recognition, simple algorithm with minimal physiological distur-
bance, and close focusing on intestinal viability. The step-wise
management modality takes CT venography as main diagnostic
method, initial anticoagulation as the treatment cornerstone,
prompt endovascular therapies as key recanalization technique,
coupled with damage control surgery operation and operative
thrombectomy, has the potential to improve clinical outcome
signiﬁcantly. This strategy evolves in a step-up manner based on
continuous assessment of intestinal viability and thrombus evolu-
tion (Fig. 3).
Due to the rareness of ASMVT, it is difﬁcult to organize a clinical
random control trial. Current treatment algorithms are mainly
dependent on surgeon’s clinical experience and personal judgment,
with weak basis of evidence. There are still lots of open questions in
this area. Initial catheter-directed thrombolysis and local anti-
coagulation are better than early surgery in ASMVT patients
without peritonitis, but no comparative results are available among
patients with peritonitis. Deﬁnitive serum markers for early diag-
nosis of ASMVT are in urgent need due to the low speciﬁcity and
limited clinical application of existing targets [99]. No method of
differentiation between transmural and mucosal necrosis is avail-
able before bowel resection. There are no studies to help establish
the indication of endovascular treatment for MVT. Criteria for
different routes of transcatheter thrombolysis, for speciﬁc etiology,
diverse thrombus location and extent, are lacking. All these ques-
tions have fueled more clinical evaluation and animal experiments
in the future.
This new stepwise management strategy for ASMVT is an inte-
gration of modern recanalization techniques rather than a technical
innovation. With this strategy, the mortality has decreased to 3% in
the single institution’s experience of 34 cases of MVT at Istanbul
university recently [100]. More studies with large series and sys-
tematic reviews are needed to clarify the effect and safety of this
modern treatment strategy further.
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